Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NT026
- Development stage
- Preclinical
- Lead developer
- Chengdu Newray Medical Technology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NT026 is a preclinical radioligand therapy (RLT) candidate being developed by Chengdu New Radiomedicine Technology for the treatment of solid tumors. As of 2024, the program is in the "Hits" stage of discovery, which represents the earliest phase of preclinical development. The specific molecular target and the therapeutic radioisotope utilized in the conjugate have not been publicly disclosed by the developer. The therapy is designed to selectively bind to tumor-associated antigens to deliver localized ionizing radiation, aiming to induce DNA damage and cell death in malignant tissues while minimizing off-target effects to healthy organs.
Beyond the preview
Go deeper on NT026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NT026.